Person:
KOÇ, EMİNE RABİA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KOÇ

First Name

EMİNE RABİA

Name

Filters

20232
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Sectoral and quadrant evaluation of the peripapillary retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in patients with multiple sclerosis
    (Galenos Publ House, 2023-12-01) Yazici, Alper; Koç, Emine Rabia; KOÇ, EMİNE RABİA; Sarıdaş, Furkan; SARIDAŞ, FURKAN; Turan, Ömer Faruk; 0000-0002-1367-240X; 0000-0001-5945-2317; JCO-1811-2023; HSB-2700-2023
    Objective: To evaluate the peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell-inner plexiform layer thickness (GC-IPL) in patients with multiple sclerosis (MS) by sector and quadrant.Materials and Methods: Seventy-eight eyes of 39 patients with MS and 82 eyes of 41 healthy participants were analyzed using spectral domain optical coherence tomography. Our study defined MS eyes with optic neuritis (ON) as MS ON eyes and those without ON as MS non-ON eyes. Comparisons of the GC- IPL and pRNFL thicknesses were assessed and the measurements compared with healthy controls (HCs).Results: The comparison of the average and three quadrants (superior, inferior, and temporal) measurements of the pRNFL thickness and the average and six quadrant measurements of the GC-IPL thickness between the MS ON eyes and the MS non-ON eyes revealed statistically significant differences (P < 0.05). The average and four quadrants thickness of pRNFL and the average and six quadrants thickness of GC-IPL were significantly reduced in a comparison of MS ON vs. HC with MS non-ON vs. HC eyes (P < 0.05).Conclusion: The evaluation of pRNFL and GC-IPL thicknesses in MS ON and MS non-ON eyes may be beneficial in determining the central nervous system axonal integrity.
  • No Thumbnail Available
    Publication
    Efficacy of accelerated vaccination against hbv to achieve antibody formation in multiple sclerosis patients receiving anti-cd20 therapy
    (Wolters Kluwer Medknow Publications, 2023-09-01) KOÇ, EMİNE RABİA; SARIDAŞ, FURKAN; TURAN, ÖMER FARUK; Turan, Omer Faruk; Özkaya, Güven; ÖZKAYA, GÜVEN; Mengüç, Bedirhan; MENGÜÇ, BEDİRHAN; Minaz, Sema Nur; MİNAZ, SEMA NUR; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Bioistatistik Anabilim Dalı.; 0000-0002-0264-7284; 0000-0001-5945-2317; 0000-0003-0297-846X; HSB-2700-2023; JCO-1811-2023
    Aim:Ocrelizumab is a monoclonal antibody that has been approved for use in both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Since ocrelizumab acts on B cells, it also affects humoral immunity, thus reducing the vaccine response. In this study, we aimed to elucidate the relationship between the antibody response following rapid vaccination against hepatitis B virus (HBV) in multiple sclerosis (MS) patients receiving ocrelizumab treatment, and the time of vaccination.Materials and Methods:A total of 220 MS patients were included in this retrospective analysis. The patients' baseline HBV serostatuses (HbsAg, Anti-HbsAb, Anti-HbcAb), previous drug history for MS, whether they were vaccinated against HBV in the past, vaccination status before or after ocrelizumab treatment, and protective antibody titers according to vaccination times, occult HBV incidence and initiation of antiviral treatment were evaluated.Results:Forty-nine percent of MS patients using ocrelizumab were not vaccinated against HBV. The patients were divided into three groups according to their vaccination status as: individuals vaccinated in the past (7.3%, n = 16), vaccinated before treatment (4.5%, n = 10), and vaccinated after treatment (22.3%, n = 49). The antibody titers of the patients in the 6th month after ocrelizumab treatment were measured as 78 mIU/ml, 193 mIU/ml, and 0, respectively. The number of patients with occult HBV infection was 38.Conclusion:In patients with a suspected diagnosis of MS, HBV serostatus should be evaluated at the beginning and if necessary, patients should be vaccinated in the early period. Vaccinating patients at least 1 month before initiating multiple sclerosis treatment is more effective in terms of protective antibody formation.